As of today (2024-04-16), Cerevel Therapeutics Holdings's share price is $41.74. Cerevel Therapeutics Holdings's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $3.72. Hence, Cerevel Therapeutics Holdings's Price to Tangible Book Ratio of today is 11.24.
The historical rank and industry rank for Cerevel Therapeutics Holdings's Price-to-Tangible-Book or its related term are showing as below:
CERE'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.48 Med: 8.87 Max: 11.41
Current: 11.22
During the past 5 years, Cerevel Therapeutics Holdings's highest Price to Tangible Book Ratio was 11.41. The lowest was 5.48. And the median was 8.87.
CERE's Price-to-Tangible-Book is ranked worse than 89.69% of 1222
companies
in the Biotechnology industry
Industry Median: 2.81
vs CERE: 11.22
A closely related ratio is called PB Ratio. As of today, Cerevel Therapeutics Holdings's share price is $41.74. Cerevel Therapeutics Holdings's Book Value per Sharefor the quarter that ended in Dec. 2023 was $3.72. Hence, Cerevel Therapeutics Holdings's P/B Ratio of today is 11.24.
Cerevel Therapeutics Holdings Price-to-Tangible-Book Historical Data
The historical data trend for Cerevel Therapeutics Holdings's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Cerevel Therapeutics Holdings Annual Data
Trend
Dec19
Dec20
Dec21
Dec22
Dec23
Price-to-Tangible-Book
-
5.48
8.27
9.47
11.41
Cerevel Therapeutics Holdings Quarterly Data
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Price-to-Tangible-Book
9.47
8.86
14.27
12.60
11.41
Competitive Comparison
For the Biotechnology subindustry, Cerevel Therapeutics Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cerevel Therapeutics Holdings Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, Cerevel Therapeutics Holdings's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Cerevel Therapeutics Holdings's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Cerevel Therapeutics Holdings Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Cerevel Therapeutics Holdings (Cerevel Therapeutics Holdings) Business Description
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CERE has been successfully added to your 